“An FDA-approved GHRH analog used for GH deficiency diagnosis and treatment, with a favorable safety profile.”

Sermorelin binds to the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary — a Gs-coupled GPCR. GHRHR activation elevates cAMP via adenylyl cyclase, which activates PKA and triggers GH gene transcription and pulsatile GH secretion. The pituitary’s natural somatostatin feedback mechanism remains intact with sermorelin, preventing excessive GH accumulation and maintaining physiological pulsatility. Sermorelin also stimulates pituitary cell proliferation and GH synthesis over time, potentially restoring pituitary GH reserve that has declined with age. Unlike exogenous HGH, sermorelin-stimulated GH release is subject to normal hypothalamic regulation, including suppression by hyperglycemia and stimulation by sleep and exercise, preserving the natural GH secretory pattern.